Maurie Markman, MD

Evidence generated from the randomized study design may be largely ignored by an individual or a community of physicians if the results or strategies being examined do not align with existing beliefs or bias, local practice and referral patterns, and other potentially highly relevant factors unrelated to the trial outcome.

The oncology clinical and research communities should demand that essential clinical trials and objectively valid evidence for efficacy and toxicity be obtained and reported before any regulatory agencies or national/international cancer societies support this strategy as a “standard of care” for cancer pain management.

It is critical to inquire what is wrong with hope, if it helps patients through their journey while not interfering with likely necessary end-of-life decisions when these are required to be made.

The recent technological advances in medicine and related fields have encouraged a belief among many that there is little technology will not be able to accomplish in improving cancer-related clinical outcomes, but it must be acknowledged that clinical medicine and cancer biology are extremely complex arenas.

Considering the decades of clinical investigation involving cytotoxic therapy of malignant disease, it is remarkable— even disconcerting—just how little is understood about the optimal delivery of this critical cancer treatment strategy.

The term statistically significant is almost certainly beautiful music to the ears of clinical investigators and pharma/biotech companies. However, concern develops when one inquires how the most common test of significance, the P value, is used in clinical investigative efforts and whether at times this is more harmful than helpful within the domain of cancer medicine.

The immediate future of clinical investigation in ovarian cancer is remarkably exciting, with a number of novel agents and combination strategies currently being examined in multiple clinical trials.

Stunning technological advances in the ability to examine the molecular structure of human DNA have significantly reduced the time and costs associated with this process.

It is essential to appreciate that precision cancer medicine is a process, not an event.

The model of an independent and self-regulating academic medical community continues to be challenged through widely reported accusations of serious scientific misconduct, failure of investigators to report potential financial conflicts of interest, and suggestions of inadequate transparency related to the questionable role of academic researchers in the analysis and reporting of industry-sponsored clinical trial results.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the concept of precision medicine in gynecologic cancers.

The concept of chronic disease management in cancer has been and continues to be inadequately considered.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the cost effectiveness of precision medicine in gynecologic cancers.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses unmet needs in endometrial and cervical cancers.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the treatment of ovarian cancer as a chronic disease.

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

Maurie Markman, MD, discusses how to address the important issue of survival following a cancer diagnosis.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, 2018 Giant of Cancer Care for Gynecologic Cancers, discusses unmet needs in rare gynecologic cancers.

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

Maurie Markman, MD, discusses the steps that the scientific community needs to take to increase public acceptance of the vaccine against the human papillomavirus.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the concept of biosimilars in oncology.

Maurie Markman, MD discusses the importance of objective evidence when using a combination approach as opposed to a single-agent treatment.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Maurie Markman, MD, discusses the search for less toxic strategies for the treatment of cancer that may lessen the negative impact on quality of life while maintaining therapeutic efficacy.

Maurie Markman, MD, discusses privacy concerns associated with genetic testing.

Maurie Markman, MD, discusses the clinical benefit of early-stage trials.

Maurie Markman, MD, reflects on how technological advances have impacted translational science and clinical medicine.

In recent years there has been much discussion about the serious limitations of the conduct and interpretation of randomized trials examining the utility of antineoplastic drug therapy.

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.